COSCIENS Biopharma Inc T.CSCI

New England Journal Of Medicine: Inflammation

[prophetoffactz]

Today's New England Journal of Medicine.

This article supports call to extend the risk period for cardiovascular disease beyond 10 years. Importance of inflammation also supported. 
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women | New England Journal of Medicine (nejm.org)

This would appear to support a potentially safe and well tolerated neutraceutical pill to treat early inflammation well in advance. Visionary Gilles Gagnon's oat beta glucan and avenanthramide chewy products as well as avenanthramide oat flour would also seem significant. Using Juvente on the skin daily may also help address systemic inflammation. This company has a potential multi-product program for complete oat care as the importance of inflammation grows in recognition.

@EricTopol

 

Beyond LDL cholesterol, the importance of inflammation (as reflected by hs-CRP) and Lp(a) for determining risk of adverse cardiovascular outcomes in a 30-year study of ~28,000 healthy women

[prophetoffactz]

Addressing inflammation, LDL and Lipoprotein-a beyond current 10 year disease management strategies are recognized in the article. This could be the sweet spot for neutraceutical options. For cardiovascular disease: Avenanthramide for inflammation, beta glucan for LDL, CoQ10 for Lipoprotein-a. Perplexity Ai: Coenzyme Q10 (CoQ10) has been shown to have a significant effect on lowering plasma